MajorSelective serotonin reuptake inhibitors×Serotonin antagonist and reuptake inhibitor (SARI) antidepressant
Updated · Methodology
Mechanism
Trazodone prolongs the QT interval, and postmarketing reports include torsade de pointes (trazodone label, US Food and Drug Administration, FDA; trazodone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Fluoxetine can also prolong the QT interval: postmarketing cases of QT prolongation and ventricular arrhythmia, including torsade de pointes, have been reported. The documents of both drugs warn that their effects on QT may add up (fluoxetine FDA label and AEMPS SmPC; trazodone FDA label). Both drugs increase serotonin activity and can lower blood sodium (fluoxetine SmPC, AEMPS; trazodone FDA label). Serotonin syndrome has been described when trazodone was combined with selective serotonin reuptake inhibitors (SSRIs), the group fluoxetine belongs to (trazodone SmPC, AEMPS). Rare cases of raised trazodone plasma levels with adverse effects have been reported with fluoxetine, and the mechanism of this pharmacokinetic interaction is unknown (trazodone SmPC, AEMPS). Fluoxetine and its active metabolite norfluoxetine are eliminated slowly, with half-lives of 4–6 and 4–16 days, so fluoxetine stays in the body for 5–6 weeks after it is stopped (fluoxetine SmPC, AEMPS).
Symptoms
QT interval prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). Torsade de pointes, a ventricular tachycardia, causes palpitations, dizziness and fainting. Serotonin syndrome presents with agitation, hallucinations, confusion, a fast pulse, unstable blood pressure, sweating, fever, tremor, muscle jerks and rigidity, nausea, vomiting and diarrhoea (fluoxetine label, US Food and Drug Administration, FDA). Trazodone causes somnolence and a drop in blood pressure on standing, sometimes with fainting, more often in older people (trazodone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Low blood sodium causes headache, difficulty concentrating, confusion, weakness and unsteadiness that can lead to falls (trazodone FDA label).
Management
The US Food and Drug Administration (FDA) labels of fluoxetine and trazodone both say to avoid combining each drug with other drugs that prolong the QT interval, and each of the two prolongs QT according to its own documents (fluoxetine and trazodone FDA labels). The Spanish summaries of product characteristics (SmPC) of both drugs are softer and advise caution with such combinations (fluoxetine and trazodone SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The UK National Institute for Health and Care Excellence (NICE) lists adding trazodone to a selective serotonin reuptake inhibitor (SSRI) as an option when depression has had no response or a limited response to an antidepressant. NICE advises considering referral to a specialist mental health service or specialist advice, and warning the patient in advance that side effects may increase (NICE NG222). If both drugs are still used, consider an electrocardiogram (ECG) before starting fluoxetine and periodic ECGs during treatment in people with risk factors for QT prolongation and ventricular arrhythmia (fluoxetine FDA label). In stable heart disease, consider an ECG before the start (fluoxetine SmPC, AEMPS). If signs of arrhythmia appear, stop fluoxetine and record an ECG (fluoxetine SmPC, AEMPS). Avoid trazodone in people with a history of arrhythmias, symptomatic bradycardia, low potassium or magnesium, or congenital QT prolongation (trazodone FDA label). Somnolence and orthostatic hypotension from trazodone can add to the effects of other psychotropic drugs, especially in older people. Warn the patient or carer and watch these effects closely after the start and before and after each dose increase (trazodone SmPC, AEMPS). For drugs acting on the central nervous system, the fluoxetine FDA label suggests considering a lower starting dose of the added drug and slower titration (fluoxetine FDA label). Monitor for serotonin syndrome, particularly at the start of treatment and after dose increases. If it appears, stop both drugs at once and start symptomatic treatment (fluoxetine FDA label; fluoxetine and trazodone SmPCs, AEMPS). Use fluoxetine with caution together with other drugs that lower sodium, and stop trazodone in symptomatic hyponatraemia (fluoxetine SmPC, AEMPS; trazodone FDA label). Fluoxetine and norfluoxetine stay in the body for 5–6 weeks after stopping, so keep the interaction in mind when starting trazodone after stopping fluoxetine (fluoxetine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Prozac (fluoxetine) prescribing information (2026)– FDA label, DailyMed setid c88f33ed-6dfb-4c5e-bc01-d8e36dd97299, version 59, revised 01/2026, section 7.7 Drugs Metabolized by CYP2D6
- AEMPS: Ficha técnica: Fluoxetina, Fluoxetina Cinfa 20 mg (nº registro 63499) (2026)– AEMPS, CIMA, nº registro 63499 (Fluoxetina Cinfa 20 mg cápsulas duras EFG), revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Trazodona (nº registro 78585), sección 4.5 (2026)– AEMPS, CIMA, nº registro 78585 (Trazodona Normon 100 mg), revisión 06/2026, secciones 4.4 y 4.5
- FDA: RALDESY (trazodone hydrochloride) prescribing information (2026)– FDA, DailyMed setid 34708cc1-b0b2-4fd0-b9f3-7f008b457fc9 (Validus), revisión 09/2026 (versión 6), secciones 5.2, 5.3, 5.9 y 7
- NICE: Depression in adults: treatment and management (NG222), further-line treatment (2022)– NICE guideline NG222, published 06/2022, recommendations 1.9.8–1.9.9 (adding trazodone to an SSRI as a further-line option)